Distemper-Adenovirus-Parvo-Pi

Verify with FDA CVM →

36 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
4
Deaths Reported
1110.0%
Death Rate

Active Ingredients

Distemper-Adenovirus-Parvo-Pi

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 36

Most Affected Breeds

Chihuahua 5
Boxer (German Boxer) 3
Dachshund (unspecified) 3
Terrier - Bull - American Pit 3
Retriever - Labrador 3
Shih Tzu 2
Maltese 2
Shepherd Dog - German 1
Terrier (unspecified) 1
Shepherd Dog - Australian 1

Most Reported Reactions

Vomiting 17
Facial swelling (see also 'Skin') 12
Hives (see also 'Skin') 9
Lethargy (see also Central nervous system depression in 'Neurological') 8
Anaphylaxis 7
Diarrhoea 5
Death 4
Pale mucous membrane 4
Allergic reaction 3
Laboured breathing 2
Lateral recumbency 2
Hypothermia 2

Outcome Breakdown

Recovered/Normal
16 (44.4%)
Ongoing
14 (38.9%)
Died
4 (11.1%)
Outcome Unknown
2 (5.6%)

Data Summary

Metric Value
Total adverse event reports 36
Reports involving death 4
Case-fatality rate (reported events) 1110.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Distemper-Adenovirus-Parvo-Pi Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 36 adverse event reports referencing Distemper-Adenovirus-Parvo-Pi, including 4 reports in which the animal died — a 1110.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Distemper-Adenovirus-Parvo-Pi. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Distemper-Adenovirus-Parvo-Pi reports are Dog (36 reports), with Dog accounting for the largest share. Within those species, Chihuahua (5), Boxer (German Boxer) (3), Dachshund (unspecified) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Distemper-Adenovirus-Parvo-Pi are Vomiting (17), Facial swelling (see also 'Skin') (12), Hives (see also 'Skin') (9), Lethargy (see also Central nervous system depression in 'Neurological') (8). Of the 36 reports with a coded outcome, Recovered/Normal is the leading category at 44.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Distemper-Adenovirus-Parvo-Pi.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial